Published in AIDS Weekly, December 29th, 2003
"With immune function restoration possible with highly active antiretroviral therapy (HAART)," M.V. Ragni and coauthors at the University of Pittsburgh "evaluated 24 HIV-positive subjects with end-stage liver disease who were undergoing orthotopic liver transplantation (OLTX) after the availability of HAART."
"The cumulative survival among HIV-positive recipients was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.